1

Matthew Wieduwilt, MD, PhD

CURRICULUM VITAE

Matthew Joseph Wieduwilt, M.D., Ph.D.

CURRENT POSITION

4/2021-Present Professor, Department of Medicine

Mal Eager Anderson Chair in Cancer Clinical Trials

Director of Hematologic Malignancy and Cellular Therapy Program

Director of Clinical Research Development, Section of Medical Oncology

Co-Program Leader, Cancer Therapeutics Program of Stephenson Cancer Center

Chair, University of California Hematologic Malignancies Consortium.

University of Oklahoma, Stephenson Cancer Center

800 NE 10th Street, Room 6026

Oklahoma City, OK 73104

Office phone: (405) 217-8001 ext 448361

Cell phone: (415) 992-1972

Email: Matthew-Wieduwilt@ouhsc.edu

EDUCATION

8/1990-3/1994 University of California, Davis

B.S. with Honors, Biochemistry, awarded 3/1994

7/1996-6/2005 University of Texas, Southwestern Medical Center

M.D. awarded 6/2005

7/1996-6/2005 University of Texas, Southwestern Medical Center

Ph.D., Genetics and Development, awarded 6/2005

7/2005-6/2006 University of California, San Francisco Intern, Internal Medicine

7/2006-6/2008 University of California, San Francisco Resident, Internal Medicine

7/2008-6/2011 University of California, San Francisco Fellow, Hematology/Oncology

8-9/2010 University of California, San Francisco Training in Clinical Research,

Summer Workshop

LICENSES, CERTIFICATION

4/2007-Present Physician and Surgeon License, Medical Board of California

4/2021-Present Medical Doctor, Oklahoma State Board of Medical Licensure and Supervision, #38014

8/2008 Certified, Internal Medicine, American Board of Internal Medicine

11/2011 Certified, Medical Oncology, American Board of Internal Medicine

11/2011 Certified, Hematology, American Board of Internal Medicine

HONORS AND AWARDS

1994 Phi Beta Kappa University of California, Davis

2005 Alpha Omega Alpha University of Texas, Southwestern Medical Center

2012 National Center of Leadership University of California, San Diego

in Academic Medicine, Professional

Development Program for Junior Faculty

2

Matthew Wieduwilt, MD, PhD

PROFESSIONAL ORGANIZATIONS

Memberships

11/2009- Present American Society of Hematology

7/2009 - Present American Society of Clinical Oncology

11/2011 - Present American Society for Blood and Marrow Transplantation

2012 - Present Alliance for Clinical Trials in Oncology, Leukemia Committee Member

2014 - Present Founder and Chair, University of California Hematologic Malignancies

Consortium

3/2019-Present Alliance for Clinical Trials in Oncology, Transplant Committee Member

PEER REVIEWED PUBLICATIONS

1. Lindsay, LL, Wieduwilt, MJ and Hedrick, JL. Oviductin, the Xenopus laevis oviductal

protease that processes egg envelope glycoprotein gp43, increases sperm binding to envelopes, and

is translated as part of an unusual mosaic protein composed of two proteases and several CUB

domains. Biology of Reproduction 60(4), 989-995, 1999.

2. Clouthier, DE. Williams, SC, Yanagisawa, H, Wieduwilt, M, Richardson, JA and Yanagisawa, M.

Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor

deficient mice. Developmental Biology 217(1), 10-24, 2000.

3. Wieduwilt, MJ and Moasser, MM. The epidermal growth factor receptor family: biology driving

targeted therapeutics. Cellular and Molecular Life Sciences 65(10), 1566-1584 Review, 2008.

4. Meunier, D, Patra, K, Smits, R, Hägebarth, A, Lüttges, A., Jaussi, R, Wieduwilt, MJ,

Quintanilla‐Fend, L, Himmelbauer, H, Fodde, R, and Fundele, RH. Expression analysis of

Proline Rich15 (Prr15) in mouse and human gastrointestinal tumours. Molecular Carcinogenesis

50(1), 8-15, 2011.

5. Wieduwilt, MJ, Valles, F, Issa, I, Behler, CM, Hwang, J, McDermott, M, Treseler, P, O’Brien, J,

Shuman, MA, Cha, S, Damon, LE, and Rubenstein, JL. Immunochemotherapy with intensive

consolidation for primary CNS lymphoma: A pilot study and prognostic assessment by diffusion-

weighted MRI. Clinical Cancer Res. 18(4), 1146-1155, 2012.

6. Tomlin, J, Orosco, RK, Boles, S, Tipps, A, Wang, HY, Husseman, J, and Wieduwilt, M. Successful

treatment of multifocal histiocytic sarcoma occurring after renal transplantation with cladribine,

high-dose cytarabine, G-CSF, and mitoxantrone (CLAG-M) followed by allogeneic hematopoietic

stem cell transplantation. Case Rep Hematol. 2015:728260.

7. Wieduwilt, M and Giralt, S. in American Society of Hematology Self Assessment Program (ASH

SAP) 2016.

8. Jabo, B, Morgan, JW, Martinez, ME, Ghamsary, M, and Wieduwilt, MJ. Sociodemographic

disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute

lymphoblastic and acute myeloid leukemia patients. PLoS ONE. 12(4): e0174760, 2017.

9. Goodman, AM, Choi, M, Wieduwilt, M, Mulroney, C, Costello, C, Frampton, G, Miller, V,

and Kurzrock. R. Next-generation sequencing reveals potentially actionable alterations in the

majority of patients with lymphoid malignancies. JCO Precision Oncology. no. 1 (May 2017) 1-13.

3

Matthew Wieduwilt, MD, PhD

10. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby

D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf

P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz

K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl

Compr Canc Netw. 15(7):926-957, 2017.

11. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan

T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer

JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad

A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic

Leukemia, Version 1.2017. J Natl Compr Canc Netw., 15:1091-1102, 2017.

12. Wieduwilt MJ. How should we treat older adults with Ph+ adult ALL and what novel approaches

are being investigated? Best Pract Res Clin Haematol. 30:201-211, 2017, Review.

13. Lancet, JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge

D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering

A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. CPX-351 (cytarabine and daunorubicin)

liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly

diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018, 10;36(26):2684-2692.

14. Wieduwilt, MJ and Walter, R. Clinical hematopoietic cell transplantation and adoptive cell therapy

in American Society of Hematology Self-Assessment Program (ASH SAP) 2019.

15. Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo

P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. Comprehensive genomic profiling

reveals diverse but actionable molecular portfolios across hematologic malignancies: Implication

for next generation clinical trials. Cancers (Basel). 2018 Dec 21;11(1).

16. Yeshurun, M, Weisdorf, D, Rowe, J, Tallman, M, Zhang, M-J, Wang, H-L, Saber, W, de Lima, M,

Sandmaier, B, Uy, G, Kamble, R, Cairo, M, Cooper, B, Cahn, J-Y, Ganguly, S, Camitta, B,

Verdonck, L, Dandoy, C, Diaz, M, Savani, B, George, B, Liesveld, J, Mcguirk, J, Byrne, M,

Grunwald, M, Drobyski, W, Pulsipher, M, Abdel-Azim, H, Prestidge, T, Wieduwilt, M, Martino,

R, Norkin, M, Beitinjaneh, A, Seo, S, Nishihori, T, Wirk, B, Frangoul, H, Bashey, A, Mori, S,

Marks, D, and Bachanova, V. The impact of the graft-versus-leukemia effect on survival in acute

lymphoblastic leukemia. Blood Adv. 2019, 26;3(4):670-680.

17. Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M,

Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N,

Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL,

Gregory KM, Ogba N, Shah B. Guidelines Insights: Acute Lymphoblastic Leukemia, Version

1.2019. J Natl Compr Canc Netw. 2019 May 1;17(5):414-423.

18. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang

M, Sayre PH, Boyer W, Gaensler KM, Anderson K, Munster PN, Andreadis C. Histone deacetylase

inhibition with panobinostat combined with intensive induction chemotherapy in older patients with

acute myeloid leukemia: Phase I study results. Clin Cancer Res. 2019 May 31. pii:

clincanres.0171.2019. doi: 10.1158/1078-0432.CCR-19-0171. [Epub ahead of print].

19. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima

M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis

G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz

K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory

4

Matthew Wieduwilt, MD, PhD

KM, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice

Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:721-749.

20. Vu K, Wu CH, Yang CY, Zhan A, Cavallone E, Berry W, Heeter P, Pincus

L, Wieduwilt MJ, William BM, Andreadis C, Kaplan LK, McCormick F, Porcu P, Brammer

JE, Ai WZ. Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed

or refractory T-cell lymphoma: results of a phase I dose-escalation study. Clin Cancer Res. 2019

Nov 26. pii: clincanres.2152.2019. doi: 10.1158/1078-0432.CCR-19-2152. [Epub ahead of print]

21. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar

B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute

lymphoblastic leukemia. Blood Adv. 2020;4(3):449-457.

22. Schwartz MS, Wieduwilt MJ. CSF3R truncation mutations in a patient with B-cell acute

lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib. Leuk Res Rep.

2020;14:100208.

23. Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML,

Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F,

Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E,

Recher C, Stiff PJ, Pettit KM, Lowenberg B, Church SE, Anderson E, Vadakekolathu J,

Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran

K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, and

DiPersio, JF. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia.

Blood. 2020 Sep 14:blood.2020007732. doi: 10.1182/blood.2020007732. Epub ahead of print.

24. Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, Rettig MP, Aldoss I,

Advani AS, Godwin J, Wieduwilt MJ, Arellano M, Muth J, Yau TO, Ravandi F, Sweet K,

Altmann H, Foulds GA, Stolzel F, Middeke JM, Ciciarello M, Curti A, Valk PJM, Lowenberg B,

Gojo I, Bornhauser, M, DiPersio JF, Davidson-Moncada JK, and Rutella S. TP53 abnormalities

correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in

AML. Blood Adv. 2020 Oct 27;4(20):5011-5024.

25. Schwartz M and Wieduwilt MJ. New approaches to the treatment of older adults with acute

lymphoblastic leukemia. Seminars in Hematology. 2020 Jul;57(3):122-129.

26. Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A,

Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E,

Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With

Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma

Leuk. 2020 Dec 24:S2152-2650(20)31041-7.

27. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran

JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J,

Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ,

Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman

MS. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc

Netw. 2021 Jan 6;19(1):16-27.

28. Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR,

Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-

risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood

Adv. 2021 Mar 23;5(6):1719-1728.

5

Matthew Wieduwilt, MD, PhD

29. Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ,

Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T,

Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P,

Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared

to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young

adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from

CALGB 10403 and the CIBMTR. Leukemia. 2021. doi: 10.1038/s41375-021-01213-5.

OTHER PUBLICATIONS

Books and Chapters

1. Wieduwilt MJ and Damon LE. Critical care of patients with hematologic malignancies, in Irwin

and Rippe’s Intensive Care Medicine. 7th edition. Philadelphia, Pennsylvania. Lippincott Williams

and Wilkins. 2011.

2. Wieduwilt MJ and Ko A. Hematology/Oncology, in UCSF Hospitalist Handbook. 4th edition.

Mookherjee, S, Lai, C, Rennke, S, Eds. San Francisco, California. 2011.

3. Wieduwilt MJ and Damon LE. Critical care of patients with hematologic malignancies, in Irwin

and Rippe’s Intensive Care Medicine. 8th edition. Philadelphia, Pennsylvania. Lippincott Williams

and Wilkins. 2017.

4. Wieduwilt MJ. Treatment of acute lymphoblastic leukemia in adults. In Acute Leukemia: An

Illustrative Guide to Diagnosis and Treatment. Editors, A. Emadi and J.Karp. 2017.

5. Schwartz M and Wieduwilt MJ. Treatment of elderly patients with acute lymphoblastic leukemia,

in Acute lymphoblastic leukemia: Translational science and clinical management for children and

adults from the bench to the bedside. Editor, Mark Litzow. 2020

Invited Commentaries

1. Wieduwilt MJ. In the era of BCR-ABL1 inhibitors, are we closing the survival gap between

allogeneic hematopoietic cell transplantation and chemotherapy for Ph+ ALL in first complete

remission? Biol Blood Marrow Transplant. 2018;24:637-638.

Collaborator

1. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier

BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson

C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat

V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Collaborators: Hogan W, Battiwalla M, Copelan E, Hildebrandt G, Ganguly S, Majhail

N, Woolfrey A, Nivison-Smith I, Hertzberg M, Diaz MA, Jakubowski A, Ustun C, Yong A, Freytes

C, DeFilipp Z, Inamoto Y, Cahn JY, Savani B, Yared J, Bajel A, Bacher U, Uy G, Rizzieri

D, Wieduwilt M, Schultz K, Grunwald M, Kamble R, Qayed M, Brammer J, Ballen K, Khera

N, Schouten H, Bierings M, Kanakry C, Wood WA, Saad A, Savoie L, Hamilton BK, Aljurf M, Vij

R, Pawarode A, Olsson R, Wirk BM, Beitinjaneh A, Seo S, Cerny J, Akpek G, Norkin M, Nishihori

T, Lazaryan A, Sabloff M. Intravenous busulfan compared with total body irradiation pretransplant

conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. pii:

S1083-8791(17)30872-81, 2017.

6

Matthew Wieduwilt, MD, PhD

NATIONAL/INTERNATIONAL MEETING PRESENTATIONS 1. Hedrick JL, Mengshol JA and Wieduwilt MJ. Lectins as microbicides and spermicides.

Molecular Biology of the Cell (Abstracts Presented at The American Society for Cell Biology

Thirty-fourth Annual Meeting) 5 suppl., 224a, 1994. Poster presentation.

2. Wieduwilt MJ, Phelan D, Karp S, Francis D and Fogarty F. Serial course of rituximab as

effective treatment of inhibitors in adult patients with hemophilia A or B. Poster session, XXIX

International Congress of the World Federation of Hemophilia, Buenos Aires, Argentina, July

2010. Poster presentation.

3. Wieduwilt MJ, Cerny J, Akard L, Ustun C, Ravandi F, Rossetti JM, HillBT, Brown J, Kellerman

L, Van Syoc R, Reed W, Andreadis C. Phase 1 Clinical Investigation of Human Myeloid Progenitor

Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia

(AML). 56th ASH Annual Meeting and Exposition. San Francisco, California, USA. December

2014, Poster presentation.

4. Wieduwilt MJ, Thomas S, Olin RL, Logan AC, Damon LE, Martin TG, Kang M, Sayre PH, Boyer

W, Gaensler KM, Anderson K, Munster P, and Andreadis C. Panobinostat-augmented cytarabine

and daunorubicin (7+3) induction for older patients with AML or High-Risk MDS is well tolerated

and results in favorable clinical outcomes: The PanDA trial. Blood 2015 126:1337. Poster

presentation.

5. Wang ES, Schiller GJ, Heffner LT, Stoc W, Rao, AV, Robo, GJ, Westervelt P, Wieduwilt MJ,

Yang J, Prasa L, Segarini, K, and Goldberg SL. Plasma vincristine levels are 100-fold higher with

Marqibo® (Vincristine Sulfate LIPOSOME Injection) in place of standard vincristine in

combination chemotherapy of patients ≥ 60 years old with newly diagnosed acute lymphoblastic

leukemia (ALL). Blood 2015 126:2491, Poster presentation.

6. Bixby D, Wieduwilt MJ, Akard LP, Khoury HJ, Becker PS, Van Der Horst EH, Ho W, and Cortes

JE. A Phase I study of IGN523, a novel Anti-CD98 monoclonal antibody in patients with relapsed

or refractory acute myeloid leukemia (AML). Blood 2015 126:3809, Poster presentation.

7. Wieduwilt MJ, Tao L, Clarke CA, Keegan THM, Glaser SL, Gomez SL, and Martinez ME. Impact

of marital status on the survival of patients with hematologic malignancies reported to the California

Cancer Registry. ASCO Annual Meeting 2016, Poster presentation.

8. Lancet JE, Uy GL, Cortes JC, Newell LF, Lin TR, Ritchi EK, Stuart, RK, Strickland SA, Hogge D,

Solomon SR, Stone RM, Bixby DL, Kolit JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A,

Chiarella M, Louie AC, and Medeiros BC. Final results of a phase III randomized trial of CPX-351

versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. ASCO Annual

Meeting 2016, Late Breaking Abstract, Oral presentation.

9. Lancet JE, Uy GL, Cortes JC, Newell LF, Lin TR, Ritchie EK, Stuart RK, Strickland SA, Hogge D,

Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Rao A, Rubenstein S,

Stock W, Foster M, Erba H, Goldberg S, Powell B, Podolstev N, Atallah E, Warlick E, Yee K, Pagel

J, Norkin M, Barta S, Sandhu I, Frankfurt O, Gautier M, Larson M, Seiter K, Levy M, Bergeron J,

Berdeja J, Kropf P, Shemanski L, Ryan D, Chiarella M, Paulsen K, Louie A, and Medieros B. CPX-

351 treatement of previously untreated older AML patients with high risk AML markedly increases

response rate over 7+3 in patients with FLT3 mutations.. EHA21, 2016, Abstract S502.

10. Medeiro BC, Lancet, JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA,

Hogge D, Solomon SR, Stone RM, Bixby DL, Kolit JE, Schiller GJ, Wieduwilt MJ, Ryan DH,

Hoering A, Chiarella MT, Loui AC and Uy, GL. Analysis of Efficacy By Age for Patients Aged

7

Matthew Wieduwilt, MD, PhD

60–75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351

Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. 58th

Annual ASH Annual Meeting and Exposition, December 2016, Oral abstract.

11. Lancet, JE Hoering A, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland

SA, Hogge D, Solomon SR., Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt, M., Ryan

DH, Chiarella MT, Louie AC, and Medeiros BC. Survival Following Allogeneic Hematopoietic

Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with

CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis

of a Large Phase III Trial. 58th Annual ASH Annual Meeting and Exposition, December 2016, Oral

abstract.

12. Wieduwilt MJ, Jabo B, Martinez ME, Ghamsary M, and Morgan JW. Sociodemographic

Disparities in Chemotherapy and Hematopoietic Cell Transplantation Utilization Among Acute

Lymphoblastic Leukemia and Acute Myeloid Leukemia Patients. 58th Annual ASH Annual Meeting

and Exposition, December 2016, Poster presentation.

13. Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH,

Mattison RJ, Halvorson A, Devine SM, Smith S, Stone RM and Larson RA. A Phase II Study of

Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell

Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic

Leukemia: CALGB Study 10701 (Alliance). 58th Annual ASH Annual Meeting and Exposition,

December 2016, Poster presentation.

14. Wieduwilt MJ, Goodman A, Jonas BA, Cassaday RD, Castro JE, Mulroney CM, Tzachanis D and

Ball ED. L-carnitine for pegylated-l-asparaginase induced hepatotoxicity. J Clin Oncol 35, 2017

(suppl; abstr e21626). Abstract only.

15. Jain N, Klisovic RB, Stock W, Ungar D, Zeidan AM, Atallah E, McCloskey J, Heffner L, Tomlinson

B, Kantarjian HM, He S, Boni J and Wieduwilt MJ. Interim Data from a Phase 1 Study Evaluating

Pyrrolobenzodiazepine-Based Antibody Drug Conjugate Adct-402 (Loncastuximab Tesirine)

Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Abstract

#1321. Poster presented at the American Society of Hematology (ASH) 59th Annual Meeting and

Exposition; December 9-12, 2017

16. Medeiros BC, Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA,

Hogge D, Solomon SR, Stone RM, Bixby DL Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan RJ,

Chiarella M, Louie AC, and Uy GL. Rates of Adverse Events per Patient-Year in a Randomized,

Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related

Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes. Abstract #1366.

Poster presented at the American Society of Hematology (ASH) 59th Annual Meeting and

Exposition, 2017

17. Ai W, Porcu P, Berry W, Engleman J, Wieduwilt MJ, and Brammer JE. A Multicenter Phase I

Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin in

Combination with Pegylated Liposomal Doxorubicin for the Treatment of Adults with Relapsed or

Refractory Cutaneous and Peripheral T-Cell Lymphomas. Abstract #1544. Poster presented at the

American Society of Hematology (ASH) 59th Annual Meeting and Exposition, 2017.

18. Lin TL, Uy GL, Wieduwilt MJ, Newell LF, Stuart RK, Medeiros BC, Schiller GJ, Rubenstein SE,

Stock W, Warlick E, Foster M, Bixby DL, Podoltsev N, An Q, Faderl S, Louie A, and Lancet JE.

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia

with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus

Conventional 7+3 Cytarabine and Daunorubicin. Abstract #1698. Poster presented at the American

Society of Hematology (ASH) 59th Annual Meeting and Exposition, 2017

8

Matthew Wieduwilt, MD, PhD

19. Uy GL, Lancet J, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D,

Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Shemanski L, Chiarella

M, Louie AC, and Medeiros BC. Multivariate Efficacy Analysis of a Randomized, Phase 3 Study

of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML)

or AML with Myelodysplasia-Related Changes. Abstract #2647. Poster presented at the American

Society of Hematology (ASH) 59th Annual Meeting and Exposition, 2017.

20. Lancet J, Ritchie EK, Uy GL, Medeiros BC, Newell LF, Lin TL, Hogge D, Stuart RK, Strickland

SA, Solomon SR, Stone RM, Kolitz JE, Bixby DL, Schiller GJ, Wieduwilt MJ, Kovacsovics T,

Ryan RJ, Chiarella M, Louie AC, and Cortes JE. Efficacy and Safety of CPX-351 Versus 7+3 in

Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2

and Phase 3 Studies. Abstract#2657. Poster presented at the American Society of Hematology

(ASH) 59th Annual Meeting and Exposition, 2017.

21. Jonas BA, Logan AC, Jeyakumar D, Abedi M, Bejar R, Wieduwilt MJ, Oesterich LG, and Curtin,

PT. A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher

Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium

(UCHMC) Study 1503. Abstract ID #2973. Poster presented at the American Society of Hematology

(ASH) 59th Annual Meeting and Exposition, 2017.

22. Lin TL, Medeiros BC, Uy GL, Newell LF, Ritchie EK, Stuart RK, Strickland SA, Hogge D,

Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Ryan RJ,

Chiarella M, Louie AC, Lancet JE, Cortes JE. Outcomes by number of induction cycles with CPX-

351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid

leukemia (sAML). ASCO Annual Meeting 2018, Poster. J Clin Oncol 36, 2018 (suppl; abstr 7040).

23. Abboud CN, Akard LP, Andreadis C, Desai PM, Foran JM, Frankfurt O, Gill S, Hsu JW, Lister J,

Pagel JM, Schiller GJ, Solh MM, Ustun C, Wieduwilt MJ, Brown J, Wong A, Kellerman L, Van

Syoc R, Mamelok R, Ravandi F. A randomized open label exploratory controlled trial of CLT-008

myeloid progenitor cells (MPC) to decrease infections during induction for AML. ASCO Annual

Meeting 2018, Poster. J Clin Oncol 36, 2018 (suppl; abstr 7043).

24. Desai PM, Akard LP, Andreadis C, Foran JM, Frankfurt O, Hsu JW, Gill S, Lister J, Pagel JM,

Schiller GJ, Solh MM, Ustun C, Wieduwilt MJ, Brown J, Wong A, Kellerman L, Syoc RV,

Zimmerman D, Panuganti, S, Solish, S, Mandalam, R, Mamelok R, Abboud CN. Decreased

incidence of infection, use of antibacterials, and days of hospital after administration of CLT-008

myeloid progenitor cells to subjects receiving AML induction therapy: Phase 2 results, 23rd

European Hematology Association Meeting, 2018. Abstract S860. Oral presentation.

25. Advani AS, Moseley A, O'Dwyer KM, Wood B, Fang M, Wieduwilt MJ, Aldoss I, Park JH,

Klisovic R, Baer MR, Stock W, Bhave R, Othus M,, Litzow MR, Stone RM and Erba HP. Results

of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine,

Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed

Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia. Abstract ID #33. Oral

abstract presented at the American Society of Hematology (ASH) 60th Annual Meeting and

Exposition, 2018.

26. Wieduwilt MJ, Yin J, Wetzler M, Uy GL, Powell BL, Kolitz JE, Liedtke M, Stock W, Beumer JH,

Mattison RJ, Storrick E, Devine S, Smith SE, Stone RM, and Larson RA. A phase II study of

dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly-

diagnosed Ph/BCR-ABL1-positive acute lymphoblastic leukemia (Ph+ ALL): Final results of

Alliance/CALGB study 10701. Abstract #309. Oral abstract presented at the American Society of

Hematology (ASH) 60th Annual Meeting and Exposition, 2018.

26. Ryan, DH, Uy, GL, Cortes, JE, Newell, LF, Ritchie, EK, Stuart, RK, Strickland, SA, Hogge, D,

Solomon, SR, Stone, RM, Bixby, DL, Kolitz, JE, Schiller, GJ, Wieduwilt, MJ, Ryan, R, Chiarella,

9

Matthew Wieduwilt, MD, PhD

M, Louie, AC and Lancet, JE. Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older

Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes

(AML-MRC) Enrolled in a Phase 3 Study. Abstract ID #1425. Poster presented at the American

Society of Hematology (ASH) 60th Annual Meeting and Exposition, 2018.

27. Lin, TL, Cortes, JE, Newell, LF, Ritchie, EK, Stuart, RK, Strickland, SA, Hogge, D*, Solomon, SR,

Stone, RM, Bixby, DL, Kolitz, JE, Schiller, GJ, Wieduwilt, MJ, Ryan, HD, Ryan, R, Chiarella, M,

Louie, AC, and Uy, GL. The Impact of Hematopoietic Cell Transplantation on Survival: An

Exploratory Analysis of a Phase 3 Study of CPX351 Versus 7+3 in Older Patients with Newly

Diagnosed, High-Risk/Secondary AML. Abstract ID #2706. Poster presented at the American

Society of Hematology (ASH) 60th Annual Meeting and Exposition, 2018.

28. Wieduwilt, MJ, Jonas, BA, Schiller, GJ, Liu, L, Mulroney, C, Mannis, GN, Tzachanis, D, Castro,

JE, Ball, ED, Curtin, P, Andreadis, C, Logan, AC, Reiner, J, and Damon, LE. . A Phase II Study of

Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707

(Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly

Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University

of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Abstract ID #4018.

Poster presented at the American Society of Hematology (ASH) 60th Annual Meeting and

Exposition, 2018.

29. Jonas, BA, Curtin, PT, Schiller, GJ, Jeyakumar, D, Wieduwilt, MJ, Abedi, M, Bejar, R, Chow, H,

Oesterich, LG, and Logan, AC. A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the

Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University

of California Hematologic Malignancies Consortium (UCHMC) Study 1503. Abstract ID #3088.

Poster presented at the American Society of Hematology (ASH) 60th Annual Meeting and

Exposition, 2018.

30. Ritchie, EK, Lin, TL, Newell, LF, Stuart, RK, Solomon, SR, Stone, RM, Schiller, GJ, Wieduwilt,

MJ, Ryan, DH, Ryan, RJ, Chiarella, M, Cortes, JE. Outcomes with CPX-351 vs 7+3 by baseline

bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute

myeloid leukemia (sAML). Abstract #269017. Poster. ASCO Annual Meeting 2019.

31. Kovacsovics, T, Levy, MY, Cook, RJ, Kolitz, JE, Westervelt, P, Donnellan, WB, Stuart, RK,

Reagan, JL, Tsai, ML, Wieduwilt, MJ, Maris, MB, Stevens, DA, Yang, J, Arana-Yi, C, Safah,H,

Marcus, SG, Shami, PJ. A Randomized Phase 2 Trial of CX-01 with Standard Therapy in Elderly

Patients with Acute Myeloid Leukemia (AML). Abstract #27029. Oral. ASCO Annual Meeting

2019.

32. Schwartz, MS, Jeyakumar, D, Damon, LE, Schiller, GJ, Wieduwilt, MJ. A Phase I/II study of

blinatumomab in combination with pembrolizumab for adults with relapsed or refractory B-lineage

acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium

Study 1504. Abstract #258349. Poster. ASCO Annual Meeting 2019.

33. Kambhampati, S, Fakhri, B, Ai, W, Kaplan, LD, Tuscano, J, Wieduwilt, MJ, Sudhindra, A, Hwang,

J, Reiner, J, Martinelli, M, Aoun, C, Ta, T, Le, D, Padilla, M, Crawford, E, Andreadis, C. A Phase

1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in

Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Abstract ID #2828. Poster

presented at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition, 2019.

34. Uy, GL, Aldoss, I, Foster, MC, Sallman, DA, Sweet, KL, Rizzieri, DA, Sayre, PH, Advani, AS

Emadi, A, Wieduwilt, MJ, Vey, N, Ciceri, F, Carrabba, MG, Moyo, T, Church, SE, Rettig, MP,

Arellano, ML, Godwin, JE, Löwenberg, B, Huls, G, Ravandi, F, Muth, J, Tran, K, Jongen-

Lavrencic, M, Timmeny, E, Topp, MS, Paolini, S, Guo, K, Curtis, T, Zhao, J, Vadakekolathu, J,

Wigginton, JM, Bonvini, E, Rutella, S, Walter, RB MS30, Davidson-Moncada, JK, DiPersio, JF.

10

Matthew Wieduwilt, MD, PhD

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for

Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. Abstract ID

#733. Oral abstract presented at the American Society of Hematology (ASH) 61st Annual Meeting

and Exposition, 2019.

35. Wieduwilt, MJ, Stock, W, Advani, AS, Luger, SM, Larson, RA, Tallman, MS, Appelbaum, FR,

Zhang, M-J, Bo-Subait, K, Sandmaier, BM, de Lima, M, Kebriaei, P, Litzow, M, Saber,

W, Weisdorf, DJ. Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy

Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and

Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission:

Comparison of CALGB 10403 to Patients Reported to the CIBMTR. Abstract ID #261. Oral abstract

presented at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition, 2019.

36. Lin, TL, Ryan, DH, Ritchie, EK, Strickland, SA, Hogge, DE, Solomon, SR, Kolitz, JE, Schiller, GJ,

Wieduwilt, MJ, Ryan, RJ, Faderl, S, Cortes, JE. Efficacy and Safety of CPX-351 Versus 7+3 in a

Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia

(AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission. Abstract ID #1316.

Poster presented at the American Society of Hematology (ASH) 61st Annual Meeting and

Exposition, 2019.

37. Schwartz, M, Damon, LE, Jeyakumar, D, Costello, CL, Tzachanis, D, Schiller, GJ, Reiner, J, and

Wieduwilt, MJ. Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with

Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California

Hematologic Malignancies Consortium Study 1504. Abstract ID #3880. Poster presented at the

American Society of Hematology (ASH) 61st Annual Meeting and Exposition, 2019.

38. Ryan, DH, Newell, LF, Ritchie, EK, Strickland, SA, Hogge, DE, Solomon, SR, Stone, RM, Schiller,

GJ, Wieduwilt, MJ, Ryan, RJ, Faderl, S, Cortes, JE. Outcomes in Patients with Acute Myeloid

Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with

CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Abstract ID #3842. Poster presented at the

American Society of Hematology (ASH) 61st Annual Meeting and Exposition, 2019.

39. Lin T, Ryan DH, Ritchie EK, Strickland SA, Hogge DE, Solomon SR, Kolitz JE, Schiller GJ,

Wieduwilt MJ, Ryan RJ, Faderl, Sand Cortes JE. Efficacy and Safety of CPX-351 Versus 7+3 in a

Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia

(sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission.

Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2020. Abstract 137. Poster.

40. Ryan DH, Newell LF, Ritchie EK, Strickland SA, Hogge DE, Solomon SR, Schiller GJ, Wieduwilt

MJ, Ryan RJ, Faderl S, and Cortes JE. Outcomes in Patients with Acute Myeloid Leukemia with

Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus

7+3: Phase 3 Exploratory Analysis. Transplantation & Cellular Therapy Meetings of ASTCT and

CIBMTR, 2020. Abstract 9. Oral presentation.

41. Esteghamat N, Anderson J, Asmuth D, Luxardi G, Pollard R, Lee JY, Noy A, Kaplan LD,

Wieduwilt MJ, Beegle J, Maciel H, and Abedi M. Early Safety Data of a Phase I Stem Cell Gene

Therapy for HIV Mediated By Lentivector Transduced, Pre-Selected CD34+ Cells . Transplantation

& Cellular Therapy Meetings of ASTCT and CIBMTR, 2020. Late breaking abstract 6. Poster.

42. Lancet, JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon

SR, Bixby D, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Chang Y-L, Cortes J.

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly

diagnosed high-risk/secondary AML. ASCO 2020 Annual Meeting, Abstract 7510 Poster. J Clin

Oncol 38: 2020 (suppl; abstr 7510).

11

Matthew Wieduwilt, MD, PhD

43. Lai, C, Vadakekolathu, J, Reeder, S, Church, SE, Ballesteros-Merino, C, Aldoss, I, Advani, AS,

Godwin, JE, Wieduwilt, MJ, Arellano, ML, Uy, GL, Ravandi, F, Foster, MC, Gyan, E, Stiff, PJ,

Vey, N, Emadi, A, Carrabba, MG, Walter, RB, Sayre, PH, Tran, K, Timmeny, E, Rettig, MP,

Kaminker, P, Muth, J, Guo, K, Yau, TO, Valk, PJM, Lowenberg, B, Gojo, I, Bornhäuser, M,

DiPersio, JF, Davidson-Moncada, JK and Rutella, S. TP53 abnormalities correlate with immune

infiltration and associate with response to flotetuzumab immunotherapy in Acute Myeloid

Leukemia. Poster presented at the American Society of Hematology (ASH) 62nd Annual Meeting

and Exposition, 2020.

44. Uy, GL, Rettig, MP, Christ, S, Aldoss, I, Byrne, MT, Erba, HP, Arellano, ML, Foster, MC, Godwin,

JE, Ravandi, F, Sayre, PH, Advani, AS, Wieduwilt, MJ, Emadi, A, Michaelis, LC, Stiff, PJ,

Wermke, M, Vey, N, Chevalier, P, Gyan, E, Recher, MD, C, Ciceri, F, Carrabba, MG, Curti, AP,

Huls, G, Topp, MS, Jongen-Lavrencic, M, Muth, J, Curtis, T, Collins, MB, Timmeny, E, Guo, K,

Zhao, J, Tran, K, Kaminker, P, Patel, P, Bakkacha, O, Jacobs, K, Kostova, M, Seiler, J, Lowenberg,

B, Rutella, S, Walter, RB, Bonvini, E, Davidson-Moncada, JK and DiPersio, JF. Prophylactic

ruxolitinib for cytokine release syndrome (CRS) in relapse/refractory (R/R) AML patients treated

with flotetuzumab. Poster presented at the American Society of Hematology (ASH) 62nd Annual

Meeting and Exposition, 2020.

45. Vadakekolathu, J, Yau, TO, Church, SE, Rettig, MP, Aldoss, I, Uy, GL, Vey, N, Emadi, A, Sayre,

PH, Walter, RB, Foster, MC, Arellano, ML, Godwin, JE, Wieduwilt, MJ, Byrne, MT, Michaelis,

LC, Stiff, PJ, Carrabba, MJ, Chevalier, P, Gyan, E, Recher, C, Advani, AS, Wermke, M, Erba, HP,

Ciceri, F, Huls, G, Jongen-Lavrencic, M, Ravandi, F, Curti, A, Topp, MS, Muth, J, Kaminker, P,

Lowenberg, B, Gojo, I, Luznik, L, DiPersio, JF, Davidson-Moncada, JK and Rutella, S. Immune

senescence and exhaustion correlate with response to flotetuzumab, an investigational CD123×CD3

bispecific dart® molecule, in acute myeloid leukemia. Poster presented at the American Society of

Hematology (ASH) 62nd Annual Meeting and Exposition, 2020.

46. Aldoss, I, Uy, GL, Vey, N, Emadi, A, Sayre, PH, Walter, RB, Foster, MC, Arellano, ML, Godwin,

JE, Wieduwilt, MJ, Byrne, MT, Michaelis, LC, Stiff, PJ, Carrabba, MG, Chevalier, P*, Gyan, E,

Recher, C, Advani, AS, Wermke, M, Erba, HP, Ciceri, F, Huls, G, Jongen-Lavrencic, M, Topp, MS,

Curti, A, Ravandi, F, Rettig, MP, Muth, J, Collins, MB, Timmeny, E, Guo, K, Zhao, J, Tran, K,

Kaminker, P, Patel, P, Bakkacha, O, Curtis, T, Jacobs, K, Kostova, M, Seiler, J, Lowenberg, B,

Rutella, S, Bonvini, E, Davidson-Moncada, JK and DiPersio, JF. flotetuzumab as salvage therapy

for primary induction failure and early relapse acute myeloid leukemia. Oral abstract presented at

the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition, 2020.

47. Lancet, JE, Uy, GL, Newell, LF, Lin, T, Hogge, DE, Solomon, SR Schiller, GJ, Wieduwilt, MJ,

Ryan, DH, Faderl, S, Chang, Y-L and Cortes, JE.. Five-year final results of a phase 3 study of CPX-

351 Versus 7+3 in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia

(AML): Outcomes by age subgroup and among responders. Oral abstract presented at the American

Society of Hematology (ASH) 62nd Annual Meeting and Exposition, 2020.

48. Uy, GL, Newell, LF, Lin, T, Goldberg, SL, Wieduwilt, MJ, Ryan, RJ, Faderl, S and Lancet, JE.

Long-term outcomes of allogeneic hematopoietic cell transplantation in patients enrolled in CPX-

351-301, a randomized phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed,

high-risk and/or secondary AML. Poster presented at the American Society of Hematology (ASH)

62nd Annual Meeting and Exposition, 2020.

49. Costello, CL, Brookhart, B, Wieduwilt, MJ, Shah, N, Mulroney, C and Ball, ED. Phase 2 study of

the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy

in relapsed/refractory multiple myeloma: Stage I results. Poster presented at the American Society

of Hematology (ASH) 62nd Annual Meeting and Exposition, 2020.

50. Wieduwilt, MJ, Metheny, L, Zhang, M-J, Wang, H, Estrada-Merly, N, de Lima, M, Litzow, M,

Partow Kebriaei, P, Hourigan, CS, Weisdorf, DJ and Saber, W. Comparison of haploidentical donor

12

Matthew Wieduwilt, MD, PhD

hematopoietic cell transplantation using post-transplant cyclophosphamide to matched-sibling,

matched-unrelated, mismatched-unrelated, and umbilical cord blood donor transplantation in adults

with acute lymphoblastic leukemia: A CIBMTR study. Oral abstract presented at the American

Society of Hematology (ASH) 62nd Annual Meeting and Exposition, 2020.

51. Cortes, JE, Hogge, DE, Solomon, SR, Schiller, GJ, Wieduwilt, MJ, Ryan, DH, Faderl, S, Chang,

Y-L, and Lin, TL, Five-year final results of a phase 3 study of CPX-351 versus 7+3 in older adults

with newly diagnosed high-risk/secondary acute myeloid leukemia (AML): Outcomes by age

subgroup and among responders Transplantation & Cellular Therapy Meetings of ASTCT and

CIBMTR, 2021. Abstract 135. Poster.

52. Uy, GL, Newell, LF, Goldberg, SL, Wieduwilt, MJ, Ryan, DH, Faderl, S, and Lin, TL. Long-term

outcomes of allogeneic hematopoietic cell transplantation in patients enrolled in CPX-351-301, a

randomized phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk

and/or secondary AML. Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR,

2021. Abstract 62. Oral.

PATENTS

1. Patent No. US 6,846,807 B1, Issued 1/25/05

Colorectal neoplasia prophylaxis

Inventors: Jonathan Graff and Matthew Wieduwilt

Assignee: Board of Regents, The University of Texas System

RESEARCH

Interventional Clinical Trials

Investigator-initiated

12/2013-Present Study chair, Principal Investigator. “A Phase II study of punctual, cyclic, and intensive

chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis for adults with

acute lymphoblastic leukemia and lymphoblastic lymphoma.” Sponsor: UCSD, Investigator-initiated, Multicenter, UC Hematologic Malignancies Consortium Study

1401. Funding: Servier, Lediant. NCT02043587.

7/2017-Present Study chair, Principal Investigator. “A Phase I/II study of blinatumomab in combination

with pembrolizumab (MK-3475) for adults with relapsed or refractory B-lineage acute

lymphoblastic leukemia with high bone marrow lymphoblast count: A University of

California Hematologic Malignancies Consortium Study” Sponsor: UCSD, Investigator-initiated, Multicenter, UC Hematologic Malignancies Consortium Study 1504. Funding:

Merck, Amgen. NCT03160079.

2/2020-Present Study chair, Principal Investigator. “Phase II, single-arm, open-label clinical study of

fludarabine in combination with CPX-351 for adults with newly-diagnosed acute

myeloid : A University of California Hematologic Malignancies Consortium Protocol

(UCHMC1914)” Sponsor: UCSD, Investigator-initiated, Multicenter, UC Hematologic

Malignancies Consortium Study 1914. Funding: Jazz.

Cooperative group

13

Matthew Wieduwilt, MD, PhD

6/2013-Present Co-chair, Alliance for Clinical Trials in Oncology Study Co-Chair for Intergroup Trial

E1910 “A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-

ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults” NCT02003222.

7/2014-12/2014 Local Principal Investigator, Alliance for Clinical Trials in Oncology, CALGB 51101,

“A Randomized Phase II Trial of Myeloablative versus Non-myeloablative

Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma.

Closed to accrual. NCT01511562

2/2015–Present Co-chair, Alliance for Clinical Trials in Oncology, Study SWOG 1318, “A Phase II

Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine,

Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly

Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphocytic Leukemia

(ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/=

65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL”

NCT02143414.

4/2015-Present Study Chair, Alliance for Clinical Trials in Oncology, CALGB 10701, “A Phase II study

of dasatinib as primary therapy followed by transplantation for adults>=18 years with

newly diagnosed Ph+ acute lymphoblastic leukemia” Closed to accrual 11/2014.

NCT01256398.

5/2015-Present Local Principal Investigator, SWOG 1203, “A Randomized Phase III Study of Standard

Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine

(IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated

Acute Myeloid Leukemia (AML)”. NCT01802333.

7/2017-Present Local Principal Investigator, AMC097, “A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells. A Trial of the

AIDS Malignancy Consortium (AMC)” NCT02797470.

2/2018-Present Study Chair, Alliance for Clinical Trials in Oncology Study A041703, “A Phase II Study

of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-negative CD22-positive

B-lineage Acute Lymphoblastic Leukemia in Older Adults or Adults with Relapsed or

Refractory Disease” Current status: Open to enrollment. NCT03739814.

5/2019-Present (In development) Study Chair, Alliance for Clinical Trials in Oncology Study A161901,

“A randomized, double-blind, placebo-controlled, Phase II study of venetoclax with

reduced-intensity conditioning followed by allogeneic HCT then venetoclax

maintenance in adult patients with acute myeloid leukemia in first complete remission.”

Industry sponsored

4/2012-5/2014 Local Principal Investigator, CLT-008-02: A Phase I/II Trial of CLT-008 Myeloid

Progenitor Cells in Patients Receiving Post-Remission Therapy for High Risk Leukemia

or Myelodysplasia.” Sponsor: Cellerant. Closed to accrual. NCT01297543.

4/2012-5/2014 Local Principal Investigator, MT-2008-38: A Phase I Trial to Determine Safety and

Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused

24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation

for Hematologic Malignancies.” Sponsor: Cellerant. Closed to accrual. NCT00891137.

14

Matthew Wieduwilt, MD, PhD

1/2013-1/2014 Local Principal Investigator, CC-5013-AML- 001, “A Phase 2, Multicenter, Randomized, Open-label, Parallel-Group Study of A Lenalidomide (Revlimid®)

Regimen or A Sequential Azacitidine (Vidaza®) plus Lenalidomide (Revlimid®)

Regimen versus An Azacitidine Regimen for Therapy of Older Subjects with Newly

Diagnosed Acute Myeloid Leukemia.” Sponsor: Celgene, Closed to accrual

NCT01358734.

2/2013-11/2014 Local Principal Investigator, Celator CLTR0310-301: A Phase 3, Multicenter,

Randomized Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus

Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk

(Secondary) AML. Sponsor: Celator. Closed to accrual. NCT01696084.

2/2013-8/2014 Local Principal Investigator, TTX404 HALLMarq: A Phase 3, Multicenter, Randomized

Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposome Injection,

VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification,

and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >

60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Sponsor:

Talon. Closed to accrual. NCT01439347.

10/2013-12/2014 Local Principal Investigator, Pfizer B1931022: An Open-label, Randomized Phase 3

Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia

(ALL). Sponsor: Pfizer. Closed to accrual. NCT01564784.

6/2014-4/2015 Local Principal Investigator, IGN523-01, “A Phase 1, Open-Label Study Evaluating the

Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects with Relapsed or

Refractory Acute Myeloid Leukemia.” Sponsor: Igenica. Closed to accrual.

NCT02040506

3/2015-Present Local Principal Investigator, CLT008-03, “An open-label Phase 2 prospective,

randomized, controlled study of CLT-008 myeloid progenitor cells as a supportive care

measure during induction chemotherapy for acute myeloid leukemia” Sponsor: Cellerant. Closed to accrual.

5/2015-6/2016 Local Principal Investigator, Novartis CPKC412AUS23, “A Phase II, randomized trial

of standard of care, with or without midostaurin to prevent relapse following allogeneic

hematopoietic stem cell transplantation in patients with FLT3-ITD mutated acute

myeloid leukemia.” Sponsor: Novartis. Closed to accrual. NCT01883362.

8/2015-1/2016 Local Principal Investigator, Ambit AC220-007: A Phase 3 Open-Label Randomized

Study Of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy In Subjects

With FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To Or Relapsed

After First-Line Treatment With Or Without Hematopoietic Stem Cell Transplantation

(HSCT) Consolidation.” Sponsor: Ambit. NCT02039726.

9/2015-6/2017 Local Principal Investigator, Gilead GS-US-339-1560: “A Phase 1b, Open-Label, Dose

Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib

(GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or

Refractory Acute Lymphoid Leukemia (ALL).” Sponsor: Gilead. NCT02404220

3/2016-Present Local Principal Investigator, ADCT 402- 02. “A Phase 1, Open-label, Adaptive Dose-

escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and

Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell

Lineage Acute Lymphoblastic Leukemia (B-ALL). Sponsor: ADCT. NCT02669264

15

Matthew Wieduwilt, MD, PhD

5/2017-Present Local Principal Investigator, CNTX-CX-01-2015-AML, “A Randomized, Phase II

Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed

Acute Myeloid Leukemia” Sponsor: Cantex. NCT02873338.

Retrospective registry studies

2015-Present Study chair, CIBMTR study LK15-03, “Comparison of outcomes of older adolescents

and young adults with Philadelphia-chromosome/BCR-ABL1-negative acute

lymphoblastic leukemia receiving post-remission consolidation chemotherapy with

pediatric-inspired chemotherapy on CALGB 10403 or myeloablative allogeneic

hematopoietic cell transplantation.” Current status: Accepted, Leukemia.

2018-Present Study chair, CIBMTR study LK18-02, “Comparison of outcomes of haploidentical donor hematopoietic cell transplantation (HCT) with matched-related donor, matched-

unrelated donor, and umbilical cord blood donor allogeneic HCT for adults with acute

lymphoblastic leukemia.” Current status: Manuscript submission

ACADEMIC COMMITTEES

7/2009-6/2010 UCSF Hematology/Oncology Performance Improvement Committee. Project: Wrote

guidelines for bone marrow biopsy procedure and fellow evaluation.

7/2010-6/2011 UCSF Hematology/Oncology Performance Improvement Committee. Project:

Organized development of educational slide set of peripheral blood morphologic

findings and significance for incoming Hematology/Oncology Fellows.

10/2011-Present Member, UCSD Moores Cancer Center Pharmacy and Therapeutics sub-Committee.

Representative from Blood and Marrow Transplantation Program.

4/2012-4/2014 Member, UCSD Protocol Review and Monitoring Committee

4/2012-Present Member, UCSD Institutional Review Board

OTHER COMMITTEES

10/2011-Present Division of Bone Marrow Transplantation Quality Improvement Committee

3/2012-1/2018 Division of Bone Marrow Transplantation Clinical Resource Management Committee

OTHER PROFESSIONAL ACTIVITIES

2/2014-Present Founder and Chair, University of California Hematologic Malignancies Consortium

(UCHMC) a multi-UC cancer center effort to perform investigator-initiated clinical

trials.

Active UCHMC studies

12/2013-Present UCHMC 1401 “A Phase II study of punctual, cyclic, and intensive chemotherapy

with liposomal cytarabine (Depocyt®) CNS prophylaxis for adults with acute

lymphoblastic leukemia and lymphoblastic lymphoma” Chair: Matthew Wieduwilt,

MD, PhD (UCSD). NCT02043587.

16

Matthew Wieduwilt, MD, PhD

7/2017-Present UCHMC1504 “A Phase I/II study of blinatumomab in combination with

pembrolizumab (MK-3475) for adults with relapsed or refractory B-lineage acute

lymphoblastic leukemia with high bone marrow lymphoblast count: A University of

California Hematologic Malignancies Consortium Study” Chair: Matthew

Wieduwilt, MD, PhD (UCSD). NCT03160079.

6/2016-Present UCHMC 1606 “A Phase 1 clinical trial to evaluate obinutuzumab with high-dose

ibrutinib for the treatment of patients with chronic lymphocytic leukemia with

progressive disease on single agent ibrutinib.” Chair: Michael Choi, MD (UCSD). NCT02611908.

7/2018-Present UCHMC1809 “Phase II study of the combination of daratumumab, ixazomib,

pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple

myeloma (A University of California Hematologic Malignancies Consortium

Protocol).” Chair: Caitlin Costello, MD. (UCSD). NCT03590652.

1/2019-Present UCHMC1811 “CPX-351 plus enasidenib for relapsed acute myeloid leukemia

characterized by the IDH2 mutation.” Chair: Gary Schiller, MD (UCLA). NCT03825796.

4/2019-Present UCHMC1812 “A Phase IB trial with dose expansion evaluating CPX-351 plus

gemtuzumab ozogamicin for relapsed acute myelogenous leukemia” Chair: Gary Schiller, MD (UCLA). NCT03904251.

1/2020-Present UCHMC1913 “Phase II study of the combination of glasdegib and Vyxeos (CPX-

351) in previously untreated patients with Acute Myelogenous Leukemia with MDS

related changes or Acute myeloid leukemia evolving out of MDS”. Chair: Deepa Jeyakumar, MD (UCI). NCT04231851.

2/2020-Present UCHMC1914 “Phase II, single-arm, open-label clinical study of fludarabine in

combination with CPX-351 for adults with newly-diagnosed acute myeloid : A

University of California Hematologic Malignancies Consortium Protocol

(UCHMC1914)” Chair: Matthew Wieduwilt, MD, PhD (UCSD).

Completed UCHMC studies

10/2015-Present UCHMC 1502 “A Phase I/II Study of PiC-D (Ixazomib in Combination with

Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double

Refractory Multiple Myeloma” Chair: Joe Tuscano, MD (UCD). NCT02542657.

4/2016-Present UCHMC 1503 “Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for

the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated

Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy” Chair: Brian Jonas, MD (UCD). NCT02553941.

6/2017-Present UCHMC1607 “A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with

Bendamustine and Rituximab in Patients with Relapsed or Refractory non-Hodgkin

Lymphoma” Chair: Charalambos Andreadis, MD (UCSF). NCT02187133.

2012-Present Alliance for Clinical Trials in Oncology, Leukemia Committee Member

Active studies

17

Matthew Wieduwilt, MD, PhD

Study chair, CALGB 10701, “A Phase II study of dasatinib as primary therapy followed

by transplantation for adults>=18 years with newly diagnosed Ph+ acute lymphoblastic

leukemia” NCT01256398.

Alliance Co-Chair Intergroup Trial ECOG 1910 “A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic

Leukemia in Adults” NCT02003222.

Alliance Co-chair Intergroup study SWOG 1318, “A Phase II Study of Blinatumomab

(NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for

Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative

(Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone

and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-

Chromosome Positive (Ph+) ALL” NCT02143414.

Study Chair, Alliance for Clinical Trials in Oncology Study A041703, “A Phase II Study

of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-negative CD22-positive B-

lineage Acute Lymphoblastic Leukemia in Older Adults or Adults with Relapsed or

Refractory Disease”

2019 – Present Alliance for Clinical Trials in Oncology, Transplant Committee Member

Studies in Development

Study Chair, Alliance for Clinical Trials in Oncology Study A161901, “A randomized,

double-blind, placebo-controlled, Phase II study of venetoclax with reduced-intensity

conditioning followed by allogeneic HCT then venetoclax maintenance in adult patients

with acute myeloid leukemia in first complete remission.”

9/2013 - Present NCCN Guidelines Panel Member, Acute Myeloid Leukemia

9/2016 - Present NCCN Guidelines Panel Member, Acute Lymphoblastic Leukemia

INVITED PRESENTATIONS

1/2014 Speaker, ASH Highlights North America 2014, San Francisco, Acute lymphoblastic

leukemia

1/2014 Speaker, ASH Highlights North America 2014, Miami, Acute lymphoblastic leukemia

10/2014 Speaker, 2nd Annual Meeting of the Society for Adolescent and Young Adult Oncology:

Breaking Barriers in Acute Lymphoblastic Leukemia. Title: “Asparaginase toxicity”

Newport Beacj, Califronia.

9/2016 Program Chair and Speaker, 1st Annual UC Hematologic Malignancies Consortium

Research Symposium, San Diego, California

6/2017 Speaker, Best of ASCO 2017, San Francisco, Hematologic Malignancies – Leukemia,

Myelodysplastic Syndromes, and Allotransplant. San Francisco, California.

9/2017 Speaker, 2nd Annual UC Hematologic Malignancies Consortium Research Symposium,

San Francisco, California

18

Matthew Wieduwilt, MD, PhD

9/2018 Speaker, 3rd Annual UC Hematologic Malignancies Consortium Research Symposium,

Irvine, California

10/2018 Invited speaker, Western Regional Summit, Acute Leukemias: AML, ALL, MPN. Talk:

Current Management of Adult Acute Lymphoblastic Leukemia. Seattle, Washington.

11/2018 Invited speaker, SAYAO/CHOC ALL Think Tank. Talk: Future directions in adult Acute

Lymphoblastic Leukemia. Newport Beach, California

12/2018 Invited CME speaker in association with ASH 60th Annual Meeting 2018. CME session

chair: Susan O’Brien, MD. Talk title: “Love at First BiTE: Blinatumomab for the

Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia” San Diego,

California.

3/2019 Invited speaker, Southern California Blood Cancer Conference, LLS, Title: “Current and future management of adult acute leukemia”, Anaheim, California.

6/2019 Invited speaker, Pancreatic Cancer Consortium, “Growing Pains: Development of The University of California Hematologic Malignancies Consortium”, Los Angeles, California.

9/2019 Speaker, 3rd Annual UC Hematologic Malignancies Consortium Research Symposium,

Sacramento, California

10/2020` Speaker, 4th Annual UC Hematologic Malignancies Consortium Research Symposium,

Los Angeles, California (virtual)

TEACHING

11-12/2009, 11-12/2010 - Medical student teaching. Methods, Mechanisms, and Malignancies. Small group

leader. UCSF Medical School.

6/2010, 10/2010 - Medical student teaching. Advances in medical sciences. Small group leader. UCSF

Medical School.

3/2012 Nursing Student Lecture, Course: BMT201, Lecture title: “Relapse and Second Malignancies After Hematopoietic Cell Transplantation”

3/2012 Nursing Student Lecture, Course: BMT201, Lecture title: “Infection and Sepsis in Hematopoietic Cell Transplantation”

3/2012 Pharmacy Student Lecture, Course: SPPS 249, Principles of Pharmacology and Physiology, Lecture

title: “Hematopoietic Growth Factors”

5/2012 VA Internal Medicine Intern/Resident Noon Conference, Lecture title: “Diagnosis and Management of Acute Leukemia”

12/2014 UCSD Gastroenterology Grand Rounds “Graft-versus-host disease of the gut”

1/2013 Organized bone marrow transplantation lecture series for Hematology/Oncology fellow

2/2013 UCSD Heme/Onc Fellow Lecture: “Transplant toxicity outside of GVHD”

4/2013 Pharmacy Student Lecture, Course: SPPS 249, Principles of Pharmacology and Physiology, Lecture

title: “Hematopoietic Growth Factors”

19

Matthew Wieduwilt, MD, PhD

5/2013 UCSD Medical Student Teaching, Small group teaching “Chronic Myelogenous Leukemia”

9/2013 VA Internal Medicine Intern/Resident Noon Conference, Lecture title: “Diagnosis and Management of Acute Leukemia”

9/2013 Hillcrest Hospital Internal Medicine Intern/Resident Noon Conference, Lecture title: “Diagnosis and Management of Acute Leukemia”

9/2013 Nursing Student Lecture, Course: BMT201, Lecture title: “Relapse and Second Malignancies After Hematopoietic Cell Transplantation”

4/2014 UCSD Heme/Onc Fellow Lecture: “Diagnosis and Management of Acute Myeloid leukemia”

4/2014 UCSD Internal Medicine Intern teaching, MGUS and multiple myeloma case based learning

4-5/2014 – SOM 241 UCSD Medical Student small group teaching

9/2014 UCSD Heme/Onc Fellow Lecture: “Pre-transplant evaluation”

9/2014 UCSD Heme/Onc Fellow Lecture: “Transplant toxicity outside of GVHD”

9/2014 Leukemia and Lymphoma Society support group lecture, “Adult acute lymphoblastic leukemia”

5/2015 - Pharmacy Student Lecture, Course: SPPS 249, Principles of Pharmacology and Physiology, Lecture

title: “Hematopoietic Growth Factors”

5/2015 Medical Student Small Group Teaching, SOM 241, Hematology Course

12/2015 UCSD Heme/Onc Fellow Lecture: “Best of ASH: Acute Leukemia”

3/2016 Southern California Blood Cancer Conference 2016, Title: “Overview of adult acute leukemia:

Current and future management”

5/2016. UCSD Medical Student Lecture. Course SOM241 (Hematology). Title: “Acute leukemia”

5/2016 SOM 241 (Hematology) UCSD Medical Student small group teaching

9/2016 UCSD Heme.Onc Fellow Lecture: “Acute myeloid leukemia”

12/2016 UCSD Heme/Onc Fellow Lecture: “Best of ASH: Acute Leukemia”

5/2017 SOM 241 (Hematology) UCSD Medical Student small group teaching

5/2017 UCSD Medical Student Lecture. Course SOM241 (Hematology). Title: “Acute leukemia”

12/2017 UCSD Heme/Onc Fellow Lecture: “Best of ASH: Acute Leukemia”

11/2018 UCSD Heme/Onc Fellow Lecture: “Overview of Acute Lymphoblastic Leukemia”

12/2018 UCSD Heme/Onc Fellow Lecture: “Best of ASH: Acute Leukemia”

1/2019 UCSD Heme/Onc Fellow Lecture: “Acute Myeloid Leukemia”

9/2020 UCSD Heme/Onc Fellow Lecture: “Acute Myeloid Leukemia”

20

Matthew Wieduwilt, MD, PhD

10/2020 UCSD Heme/Onc Fellow Lecture: “Overview of Acute Lymphoblastic Leukemia”

11/2020 Alliance for Clinical Trials in Oncology Fall Meeting, Clinical Research Professionals Breakout

Session, “Hematologic Malignancies”

COMMUNITY OUTREACH

Co-founder Young Adult Leukemia and Lymphoma - with Amanda Schlichtholtz created this support group

or adolescents and young adults with blood cancers. Now run by patients for patients. Regular attendee of

meetings.

JOURNAL REVIEW

02/2012 Reviewer, Biology of Blood and Marrow Transplantation

07/2012 Reviewer, Leukemia Research

01/2015 Reviewer, Journal of the National Comprehensive Cancer Network

06/2015 Reviewer, Blood Reviews

03/2016 Reviewer, Cancer

04/2016 Reviewer, Journal of the National Comprehensive Cancer Network

09/2017 Reviewer, Blood

03/2017 Reviewer, Journal of the National Comprehensive Cancer Network

05/2017 Reviewer, ASH Education Program Book

08/2018 Reviewer, PLOS One

03/2019 Reviewer, Biology of Blood and Marrow Transplantation

08/2019 Reviewer, Biology of Blood and Marrow Transplantation

09/2019 Reviewer, Haematologica

01/2020 Reviewer, Blood Advances

01/2020 Reviewer, Blood

01/2020 Reviewer, Blood Advances

02/2020 Reviewer, Leukemia

05/2020 Reviewer, Clinical Myeloma, Lymphoma, and Leukemia

05/2020 Reviewer, Leukemia Research

05/2020 Reviewer, Biology of Blood and Marrow Transplantation

08/2020 Reviewer, PLOS One

08/2020 Reviewer, Biology of Blood and Marrow Transplantation

09/2020 Reviewer, PLOS One

09/2020 Reviewer, Cancer

10/2020 Reviewer, Blood

10/2020 Reviewer, Cancer

02/2021 Reviewer, Blood Advances

03/2021 Reviewer, Blood

03/2021 Reviewer, Blood Advances